Digest Network Come funziona
Network
/
Società
Au
Non verificato

Autobahn Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaPsichiatriaSalute

6 comunicati stampa

Guarda tutti i comunicati
21/09/2026
Industria
Psichiatria
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Ottica
Autobahn Therapeutics Reports AMPLIFY-BD Results for Elunetirom in Bipolar Depression, Highlighting Rapid, Robust, and Sustained Improvements in Depressive Symptoms and Functioning
Fonte
Autobahn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/08/2026
Industria
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons
Fonte
Autobahn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/06/2026
Industria
Psichiatria
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects
Fonte
Autobahn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Eventi
Biotecnologia
Salute
Psichiatria
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Fonte
Autobahn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
26/05/2026
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Industria
Autobahn Therapeutics Announces U.S. FDA Fast Track Designation for Elunetirom, a CNS-Directed Thyroid Hormone Receptor Agonist, for the Adjunctive Treatment of Bipolar Depression
Fonte
Autobahn Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/05/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Eventi
Industria
Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures
Fonte
Autobahn Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0